PEMETREXED MARKET ANALYSIS

Pemetrexed, sold under brand name Alimta by Eli Lilly and Company is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Alimta is a folate analog metabolic inhibitor and in combinations with certain drugs it is indicated for various diseases:

• In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC)
• As a single agent for the maintenance and treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
• As a single agent for the treatment of patients with recurrent metastatic nonsquamous non-small cell lung cancer (NSCLC) after prior chemotherapy
• In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma (MPM) whose disease is unresectable or who are otherwise not candidates for curative surgery

Global pemetrexed market size was valued at US$ 2,287.2 Million in 2022 and is expected to witness a CAGR of 2.2% over the forecast period (2022 – 2030).

Figure 1.Global Pemetrexed Market Share (%), by Distribution Channel, 2022

To learn more about this report, Request sample copy

Increasing demand of hospital pharmacies due to 340b program boosts the growth of the market over the forecast period.

Increase in the demand of hospital pharmacies due to 340b program (Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients) drives the growth of the market over the forecast period. For instance, in November 2021, according to the reports published in Science direct, an online publishing database, reported that 340b hospitals provided a significantly higher average number of medication access services compared to non-340B hospitals, whereas a higher percentage of 340B hospitals reported providing the service compared to non-340B hospitals in the U.S. These services are known to improve access and quality of care for low income populations.

Figure 2. Pemetrexed Market Share (%), by Region, 2022

To learn more about this report, Request sample copy

North America is expected to hold dominant position, owing to high prevalence of non-small cell lung cancer in the U.S

Increasing number of prevalence of non-small cell lung cancer in the U.S. drives the global pemetrexed market over the forecast period. For instance, American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) had been diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC, Non-small Cell Lung, (68%), stage IIIA NSCLC, Non-small Cell Lung Cancer (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).

Global Pemetrexed Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals.

Increasing termination on ongoing clinical trials during covid-19 in oncology department hindered the growth of global pemetrexed market. For instance, in July 2020, according to the reports published by The European Federation of Pharmaceutical Industries and Associations, a trade association and lobbying organization, over 20% of global oncology trials were halted because of the pandemic, with breast, prostate and lung cancer trials impacted the most.

Moreover, in March 2020, the National Institute for Health Research (NIHR) in the U.K. decided to prioritize COVID-19 related trials and paused all other new or ongoing trials, as well as non-COVID laboratory-based medical research.

Global Pemetrexed Market: Key Developments

• Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period. For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, an international pharmaceutical company, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.  The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly.
• For instance, on February 3, 2022, Dr. Reddy's Laboratories Ltd., a multinational pharmaceutical company along with its subsidiaries, announced that it entered into a definitive agreement to acquire Nimbus Health GmbH, a privately owned company, Dr. Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone based earn outs over the next four years. The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a treatment option for patients.

Global Pemetrexed Market: Restraints

Parenteral route of administration has to be performed under medical supervision, to avoid side effects and complications, which burdens cost on patients. The incorrect use of this therapy from parenteral route can cause liver dysfunction, refeeding syndrome, and other side effects.

Key Players

Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc.